Press releasePRNewswire
Regenxbio
RGNX · NASDAQ
$7.40+$0.25 (+3.50%)TodayMarket closed ·
Prev close $7.15
Latest news
- News
Full Transcript: Regenxbio Q2 2026 Earnings Call
- Press releasePRNewswire
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
- Press releasePRNewswire
REGENXBIO to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
- Press releasePRNewswire
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
Crude Oil Down 3%; XPeng Shares Fall After Q2 Results
- NewsVandana Singh
Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releasePRNewswire
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
- News
Regenxbio Q2 EPS $0.43 Beats $(0.03) Estimate, Sales $108.019M Miss $117.127M Estimate
- Press releasePRNewswire
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
- Press releasePRNewswire
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
- Press releasePRNewswire
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
- NewsPiero Cingari
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
- NewsVandana Singh
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments
- Press releasePRNewswire
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
- NewsAvi Kapoor
Crude Oil Surges 4%; Travelers Posts Upbeat Q2 results
- NewsAvi Kapoor
Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- News
Market-Moving News for July 17th
- Press releasePRNewswire
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releasePRNewswire
REGENXBIO Announces Proposed Public Offering of Common Stock
- Press releasePRNewswire
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
- NewsVandana Singh
What's Going On With Capricor Therapeutics Stock On Friday?
- Press releasePRNewswire
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
- NewsVandana Singh
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy
- Press releasePRNewswire
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
- News
Market-Moving News for June 22nd
- Press releasePRNewswire
REGENXBIO to Participate in Upcoming Investor Conferences
- NewsAvi Kapoor
Nasdaq Jumps Over 200 Points; Dillard's Shares Gain After Q1 Earnings
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsVandana Singh
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval
- NewsAvi Kapoor
Dow Jumps Over 250 Points; US Retail Sales Increase In April
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.